An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Trial Status: active
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Inclusion Criteria
Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy
Able to dose orally
ECOG Performance status of 0-1
No other significant underlying ocular disease
Adequate organ function
Not pregnant/nursing or planning to become pregnant. Willing to use birth control
Exclusion Criteria
Previous treatment with a Protein Kinase C (PKC) inhibitor
Concurrent malignant disease
Active HIV infection or Hep B/C
Malabsorption disorder
Unable to discontinue prohibited medication
Impaired cardiac function or clinically significant cardiac disease
Any other condition which may interfere with study interpretation or results
Additional locations may be listed on ClinicalTrials.gov for NCT05907954.